期刊文献+

子宫颈癌筛查大样本数据引发的思考 被引量:10

Insights and thinking from big data of cervical examination and human papillomavirus test
原文传递
导出
摘要 子宫颈癌是全球女性生殖道最常见由高危型人乳头瘤病毒(high-risk human papillomavirus,hr HPV)致病的恶性肿瘤,对其病变过程筛查,能够早期发现与治疗,有效遏制其发病率和死亡率。当前的筛查方法包括细胞学检查、高危型HPV检测和联合筛查(细胞学检查+高危型HPV检测)。采取何种筛查方案,对子宫颈癌的防治极为重要。目前我国对子宫颈癌筛查方案的选择存在一些困惑和争议。针对各种筛查方案的优劣性,我们对子宫颈癌筛查中获得的大样本数据进行分析,发现细胞学能有效筛查出子宫颈癌和癌前病变,高危型HPV检测的阳性检出率较高,在部分正常人群中亦可检出HPV阳性,且检测出HPV的不同型别可为临床分类管理患者和疫苗研发提供参考依据。而按筛查效果分析,细胞学联合高危型HPV检测仍是目前最佳的筛查方案。 Cervical cancer is the most common malignant tumor among women caused by high-risk human papillomavirus (hrHPV). Its precursor lesions can be early detected through the screening procedures and treated to reduce its morbidity and mortality. There are three screening methods including a cytological examination, hrHPV test and the combination of cytological examination and hrHPV test. An appropriate screening method is important for prevention and management of the cervical cancer. It is debating for choosing which screening method of the cervical cancer in China. For this purpose, we will list the results, and provide our thinking and conclusion as the following based upon the analysis of a huge number of screening data of the cervical cancer, accumulated in the KingMed laboratory during the past years.
出处 《中华临床实验室管理电子杂志》 2016年第1期8-12,共5页 Chinese Journal of Clinical Laboratory Management(Electronic Edition)
关键词 子宫颈癌 大样本数据 细胞学筛查 高危型人乳头瘤病毒 联合筛查 Cervical cancer Huge number of data Cytological screening High-risk humanpapillomavirus Combination screening
  • 相关文献

参考文献16

  • 1National Institutes of Health, National Cancer Institute. PDQCervical Cancer Prevention: Date last modified.2016. Bethesda, MD: National Cancer Institute. http://www.cancer.gov/types/cervical/hp/ cervical-treatment-pdq.
  • 2Cervical Cancer Screening with HPV Test. http://www2c.cdc.gov/ podcasts/mediaJpdf/Massad%2001 .pdf.
  • 3Zheng B, Li Z, Liang X, et al. Cervical Cytology Reporting Rates from China's Largest College of American Pathologists-Certified Laboratory with a Focus on Squamous Cell Carcinoma Cytology and Its Histopathological Follow-Up Results[J]. Acta Cytolog, 2015,59(5):399-404.
  • 4Zheng B, Austin RM, Liang X, et al. PPV of an HSIL cervical cytology result in China's largest CAP-certified laboratory[J]. J Am Soc Cytopathol, 2015,4(2): 84-89.
  • 5Zheng B, Austin RM, Liang X, et al. Bethesda System reporting rates for conventional Papanicolaou tests and liquid-based cytology in a large Chinese, College of American Pathologists-certified independent medical laboratory analysis of 1394389 Papanicolaou Test Reports[J]. Arch Pathol Lab Med, 2015,139(3):373-377.
  • 6Zeng Z, Austin RM, He X, et al. Prevalence of High-Risk Human Papillomavirus Infection in China: Analysis of 671,163 Human Papillomavirus Test Results From China's Largest College of American Pathologists-Certified Laboratory[J]. Am J Clin Pathol, 2016,145(5): 622-625.
  • 7Zeng Z, Yang H, Li Z, et al. Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Ggenotyping Results from China's Largest CAP Certified Laboratory[J]. J Cancer 2016,7(9): 1037-1043.
  • 8Zheng B, Li Z, Griffith CC, et al. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified Laboratory[J]. Cancer Cytopathol, 2015,123(7):428-434.
  • 9Cervical Cancer Screening (PDQ)-Health Professional Version [DB/OL]. [ 2015-10-07].http://www.cancer.gov/types/cervical/hp/ cervical- screening-pdq.
  • 10Zheng B, Austin M, Liang X, et al. Conventional Pap Smear Cervical Screening in 11 Rural Counties in Hainan Providence, China: Analysis of TBS Reporting Rates For 218,195 Screened Women. The American Society for Colposcopy and Cervical Pathology(ASCCP) meeting, New Orleans: 2016.

同被引文献53

引证文献10

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部